Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Booster Vaccination With NBP606 in Healthy Toddlers (The Extension Study of NBP606_PCVI_III_2013)
Latest Information Update: 21 Apr 2020
Price :
$35 *
At a glance
- Drugs NBP 606 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors SK Chemicals
- 17 Apr 2020 Status changed from recruiting to completed.
- 12 Oct 2016 New trial record